Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study

Odozor, Chioma U; Kannampallil, Thomas; Abdallah, Arbi Ben; Roles, Kristen; Burk, Carrie; Warner, Benjamin C; Alaverdyan, Harutyun; Clifford, David B.; Piccirillo, Jay F.; Haroutounian, Simon

doi:10.1097/j.pain.0000000000002639

Cited by 12 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diagnosis of COVID-19 was made based on the World Health Organization interim guidance [6] . The severity of COVID-19 was defined as severe or nonsevere following the American Thoracic Society (ATS) guidelines for community-acquired pneumonia [7] . Accordingly, severe cases with COVID-19 were defined as confirmed SARS-CoV-2 infection plus one of the following conditions: respiratory rate > 30 breaths/min, severe respiratory distress, or SpO 2 < 90% on room air.…”

Section: Clinical Examinationsmentioning

confidence: 99%

One-year self-reported neurological sequelae in older COVID-19 survivors

Li¹,

Liu²,

Yan³

et al. 2022

Ageing Neur Dis

View full text Add to dashboard Cite

Aim: With the increasing number of patients recovered from COVID-19, the long-term health consequences of this disease have attracted much attention. Neurological complications are commonly seen in the acute phase of COVID-19, especially in older adults. This study aimed to investigate the long-term neurological sequelae in older COVID-19 survivors. Methods: A total of 1438 COVID-19 survivors were recruited in this study. One year after hospital discharge, information about self-reported symptoms of the central and peripheral nervous system was collected. Comparisons of these neurological symptoms between COVID-19 survivors with severe and nonsevere cases were performed. Results: A total of 139 (53.46%) COVID-19 survivors with severe cases and 328 (27.84%) survivors with nonsevere cases reported at least one neurological symptom one year after discharge. Most of these neurological symptoms were symptoms of the central nervous system. Specifically, 126 (48.46%) survivors with severe cases and 306 (25.98%) survivors with nonsevere cases reported at least one CNS symptom. The most frequently reported symptoms were memory deficit [234 (16.27%)] and attention deficit [80 (5.56%)]. Disease severity was associated with increased risks of long-term neurological sequelae of COVID-19. Conclusion: This study demonstrated that neurological sequelae of COVID-19 are common one year after patient discharge, suggesting that the effects of COVID-19 on the neurological system are prolonged.

show abstract

Section: Clinical Examinationsmentioning

confidence: 99%

One-year self-reported neurological sequelae in older COVID-19 survivors

Li¹,

Liu²,

Yan³

et al. 2022

Ageing Neur Dis

View full text Add to dashboard Cite

show abstract

“…The largest current concern is potential associations between persistent long COVID symptoms and DSP. About 6% report neuropathy symptoms persisting beyond 1–3 months after SARS-CoV-2 infection, although other persistent symptoms, such as dysmotility, exertional intolerance and cognitive dysfunction, might include contributions from undiagnosed neuropathy 47. Given considerable overlaps in symptoms, it is not unexpected that small fibre neuropathy is the most strongly associated in early case series.…”

Section: Clinical Featuresmentioning

confidence: 99%

Advances in diagnosis and management of distal sensory polyneuropathies

Silsby

Feldman

Dortch

et al. 2023

J Neurol Neurosurg Psychiatry

Self Cite

View full text Add to dashboard Cite

Distal sensory polyneuropathy (DSP) is characterised by length-dependent, sensory-predominant symptoms and signs, including potentially disabling symmetric chronic pain, tingling and poor balance. Some patients also have or develop dysautonomia or motor involvement depending on whether large myelinated or small fibres are predominantly affected. Although highly prevalent, diagnosis and management can be challenging. While classic diabetes and toxic causes are well-recognised, there are increasingly diverse associations, including with dysimmune, rheumatological and neurodegenerative conditions. Approximately half of cases are initially considered idiopathic despite thorough evaluation, but often, the causes emerge later as new symptoms develop or testing advances, for instance with genetic approaches. Improving and standardising DSP metrics, as already accomplished for motor neuropathies, would permit in-clinic longitudinal tracking of natural history and treatment responses. Standardising phenotyping could advance research and facilitate trials of potential therapies, which lag so far. This review updates on recent advances and summarises current evidence for specific treatments.

show abstract

“…Currently, the literature on this topic is mainly composed of case reports, case series and observational studies with limitations, such as small sample size, confounding or bias, which prevent firm establishment of a causative link. [20][21][22][23][24][25] Further studies are needed to investigate this important topic.…”

Section: Complications Affecting the Peripheral Nervous Systemmentioning

confidence: 99%

Neuromuscular Complications of COVID-19: Evidence from the Third Year of the Global Pandemic

Suh

Amato

2023

Semin Neurol

View full text Add to dashboard Cite

Accumulating evidence in the third year of the global pandemic suggests that coronavirus disease 2019 (COVID-19) can cause neuromuscular complications during or after the acute phase of infection. Direct viral infection and immune-mediated mechanisms have been hypothesized. Furthermore, in patients with underlying autoimmune neuromuscular diseases, COVID-19 infection may trigger a disease flare. COVID-19 vaccines appear to be safe and effective at preventing severe illness from COVID-19. Certain vaccines are associated with an increased risk of Guillain-Barré syndrome and possibly Bell's palsy, but the absolute incidence is low, and benefits likely outweigh the risks. Newer prophylactic therapies and treatments are also becoming available for patients who may not mount a sufficient response to vaccination or have contraindications. In this article, we discuss the current available evidence on neuromuscular complications of COVID-19 and clinical considerations regarding vaccination.

show abstract

Post-acute sensory neurological sequelae in patients with severe acute respiratory syndrome coronavirus 2 infection: the COVID-PN observational cohort study

Abstract: Supplemental Digital Content is Available in the Text.Using a prospective observational study model, we compared the frequency and severity of reported peripheral neuropathy symptoms between patients with and without a SARS-CoV-2 infection.

Cited by 12 publications

References 29 publications

One-year self-reported neurological sequelae in older COVID-19 survivors

One-year self-reported neurological sequelae in older COVID-19 survivors

Advances in diagnosis and management of distal sensory polyneuropathies

Neuromuscular Complications of COVID-19: Evidence from the Third Year of the Global Pandemic

Contact Info

Product

Resources

About